Obermatt
See Similar Stocks →

Tvardi Therapeutics

NAQ:TVRD · US1407553072
PharmaceuticalsSmall

360° View

26
Price/Sales5
Price/Earnings17
Price/Book82
Dividend Yield1
Revenue Growth28
Profit Growth82
Capital Growth15
TSR 52w1
Leverage64
Liquidity81
Refinancing6
Combined29
Analyst Opinions15
Pro Holdings43
Opinion Changes50
Market Pulse88

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Employees18
Websitetvarditherapeutics.com
ISINUS1407553072
Last UpdateApr 2, 2026
Index & Theme
InflammationHepatologyChronic DiseasesRespiratoryOncologyPulmonologyBiotechnologyPharmaceutical

Description

Tvardi Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company focuses on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammat…

Analysis

Tvardi Therapeutics's 360° View rank of 26 places it below its peer average — better than 26% of its true peers.

It's lagging on growth (22) and on the expensive side (35). On safety it is financially sound (52), and the market shows favorable sentiment (53). Taken together, its Combined rank of 29 reads as below its peer average.

360° rank · history

1007550250
26
2023202420252026

All-time high

64

Jan 2025

All-time low

15

Mar 2026

Average rank

36

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
5
20
34
33
Price/Earnings
17
72
72
30
Price/Book
82
95
89
50
Dividend Yield
1
1
1
1
Value (overall)
35
54
63
33

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Tvardi Therapeutics with its peers
Contineum Therapeutics
NSQ:CTNM
80
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Coherus Oncology
NMQ:CHRS
72
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Pliant Therapeutics
NSQ:PLRX
41
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Trevi Therapeutics
NMQ:TRVI
96
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Structure Therapeutics
NMQ:GPCR
67
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
BIOAGE Labs
NSQ:BIOA
23
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →